Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 8/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8261717 | 0.92 | CHRM2 (0.51) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL14403276 | 0.90 | CHRM2 (0.50) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL8264279 | 0.89 | CHRM2 (0.48) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL1750511 | 0.89 | ESR2 (0.53) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL951850 | 0.89 | ESR2 (0.48) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL8264324 | 0.88 | CHRM5 (0.47) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3197517 | 0.88 | SLC6A3 (0.54) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL951478 | 0.88 | NR1H2 (0.47) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL8253723 | 0.88 | ESR2 (0.52) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL2240101 | 0.87 | CHRM5 (0.61) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3919056-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2970308-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3045448-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| EP-1404682-B1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK AS (DK) | 2005-09-14 | — | — | EP | disclosed |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | US | disclosed |
| US-6166037-A | Pyrrolidine and piperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHRM5 4813/4885CHRM1 4847/4885CHRM2 4833/4885 |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHRM5 4813/4885CHRM1 4847/4885CHRM2 4833/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CHRM5 4813/4885CHRM1 4847/4885CHRM2 4833/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CHRM5 4813/4885CHRM1 4847/4885CHRM2 4833/4885 |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBB, HBG1 | CHRM5 4833/4885CHRM1 4859/4885CHRM2 4822/4885 |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CHRM5 4813/4885CHRM1 4847/4885CHRM2 4833/4885 |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | PTPRO, PTPRF, PTPA | CHRM5 4600/4885CHRM1 4249/4885CHRM2 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.